BioLife Solutions, Inc. (NASDAQ:BLFS) is Roubaix Capital LLC's 9th Largest Position

Roubaix Capital LLC grew its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 90.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 280,337 shares of the medical equipment provider's stock after purchasing an additional 133,439 shares during the quarter. BioLife Solutions makes up about 3.2% of Roubaix Capital LLC's portfolio, making the stock its 9th biggest holding. Roubaix Capital LLC owned 0.64% of BioLife Solutions worth $4,555,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC purchased a new position in shares of BioLife Solutions during the 4th quarter valued at approximately $41,000. Louisiana State Employees Retirement System purchased a new position in shares of BioLife Solutions during the 4th quarter valued at approximately $283,000. Cerity Partners LLC purchased a new position in shares of BioLife Solutions during the 4th quarter valued at approximately $438,000. Conestoga Capital Advisors LLC increased its holdings in shares of BioLife Solutions by 4.2% during the 4th quarter. Conestoga Capital Advisors LLC now owns 64,847 shares of the medical equipment provider's stock valued at $1,054,000 after purchasing an additional 2,585 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in BioLife Solutions by 167.2% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 1,020 shares during the period. 93.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BLFS has been the topic of several recent analyst reports. Jefferies Financial Group initiated coverage on shares of BioLife Solutions in a report on Thursday, April 4th. They set a "buy" rating and a $22.00 price objective on the stock. StockNews.com raised shares of BioLife Solutions to a "sell" rating in a research note on Friday. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $23.40.

BioLife Solutions Price Performance

BLFS traded up $1.53 on Friday, hitting $19.54. 1,692,948 shares of the company's stock were exchanged, compared to its average volume of 427,370. The firm has a 50-day moving average price of $17.48 and a 200-day moving average price of $15.99. The stock has a market cap of $885.16 million, a price-to-earnings ratio of -13.76 and a beta of 1.69. The company has a current ratio of 2.86, a quick ratio of 1.83 and a debt-to-equity ratio of 0.06. BioLife Solutions, Inc. has a fifty-two week low of $8.92 and a fifty-two week high of $24.50.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.06. BioLife Solutions had a negative net margin of 45.84% and a negative return on equity of 12.83%. The company had revenue of $31.73 million during the quarter, compared to analysts' expectations of $29.30 million. During the same quarter in the prior year, the company earned ($0.27) EPS. As a group, equities analysts anticipate that BioLife Solutions, Inc. will post -0.6 earnings per share for the current year.

Insider Buying and Selling

In other BioLife Solutions news, CEO Greef Roderick De sold 7,249 shares of the company's stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $16.60, for a total value of $120,333.40. Following the completion of the sale, the chief executive officer now directly owns 461,854 shares in the company, valued at approximately $7,666,776.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other BioLife Solutions news, CEO Greef Roderick De sold 7,249 shares of BioLife Solutions stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $16.60, for a total transaction of $120,333.40. Following the transaction, the chief executive officer now directly owns 461,854 shares of the company's stock, valued at $7,666,776.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sarah Aebersold sold 4,000 shares of the business's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $17.65, for a total transaction of $70,600.00. Following the completion of the transaction, the insider now owns 65,843 shares in the company, valued at $1,162,128.95. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,996 shares of company stock worth $562,145. 2.70% of the stock is owned by corporate insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.